Interleukin-18: A pro-inflammatory cytokine that plays an important role in acute pancreatitis

Expert Opinion on Therapeutic Targets

Volumn 11, Issue 10, 2007, Pages 1261-1271

  Yuan, Bo Si ^a   Zhu, Ren Min ^a   Braddock, Martin ^b   Zhang, Xiao Hua ^d   Shi, Wei ^a   Zheng, Ming Hua ^c  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b ASTRAZENECA   (United Kingdom)

^c WENZHOU MEDICAL UNIVERSITY   (China)

^d NONE

Author keywords

Acute pancreatitis; IL 1 converting enzyme; IL 18; Liver injury; Oxidative stress; P2X7 receptor

Indexed keywords

A 740003; ANTIINFLAMMATORY AGENT; AZ 11645373; CYTOKINE; GAMMA INTERFERON; GLUTATHIONE PEROXIDASE; IBOCTADEKIN; INTERLEUKIN 18; INTERLEUKIN 18 ANTIBODY; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 1BETA CONVERTING ENZYME INHIBITOR; NAFAMSTAT MESILATE; PURINE P2X7 RECEPTOR; PURINE P2X7 RECEPTOR ANTAGONIST; SELENIUM; UNCLASSIFIED DRUG;

ACUTE PANCREATITIS; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; HUMAN; IMMUNE DEFICIENCY; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; LIVER INJURY; MELANOMA; NONHUMAN; OXIDATIVE STRESS; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN TARGETING; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION;

ACUTE DISEASE; ANIMALS; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-18; PANCREATITIS;

EID: 35348960036     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.11.10.1261     Document Type: Review

References (128)

1. GHAYUR T, BANERJEE S, HUGUNIN M et al.: Caspase-1 processes IFN-γ-inducing factor and regulates LPS-induced IFN-γ production. Nature (1997) 386:619-623.
2. OKAMURA H, TSUTSI H, KOMATSU T et al.: Cloning of a new cytokine that induces IFN-γ production by T cells. Nature (1995) 378:88-91.
3. BORASCHI D, DINARELLO CA: IL-18 in autoimmunity: review. Eur. Cytokine Netw. (2006) 17:224-252.
4. USHIO S, NAMBA M, OKURA T et al.: Cloning of the cDNA for human IFN-γ-inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein. J. Immunol. (1996) 156:4274-4279.
5. KOHNO K, KATAOKA J, OHTSUKI T et al.: IFN-γ-inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12. J. Immunol. (1997) 158:1541-1550.
6. ROBINSON D, SHIBUYA K, MUI A et al.: IGIF does not drive Th1 development but synergizes with IL-12 for interferon-γ production and activates IRAK and NF-κB. Immunity (1997) 7:571-581.
7. YOSHIMOTO T, TAKEDA K, TANAKA T et al.: IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-γ production. J. Immunol. (1998) 161:3400-3407.
8. DAO T, ORASHI K, KAYANO T, KURIMOTO M, OKAMURA H: Interferon-γ-inducing factor, a novel cytokine, enhances Fas ligand-mediated cytotoxicity of murine T helper 1 cells. Cell Immunol. (1996) 173:230-235.
9. TSUTSUI H, NAKANISHI K, MATSUI K et al.: IFN-γ-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones. J. Immunol. (1996) 157:3967-3973.
10. DAI SM, SHAN ZZ DR, XU H, NISHIOKA K: Cellular targets of interleukin-18 in rheumatoid arthritis. Ann. Rheum. Dis. (2007) (In Press).
11. SIVALINGAM SP, THUMBOO J, VASOO S, FONG KY: HLA-DRB1*04 gene polymorphisms and expressions profiles of interleukin-18 and interleukin-18 binding protein following in vitro stimulation in human peripheral blood mononuclear cells of healthy individuals and patients with rheumatoid arthritis. Life Sci. (2007) 80:1887-1896.
12. JOHN T, KOHL B, MOBASHERI A, ERTEL W, SHAKIBAEI M: Interleukin-18 induces apoptosis in human articular chondrocytes. Histol. Histopathol. (2007) 22:469-482.
13. SIVALINGAM SP, THUMBOO J, VASOO S, THIO ST, TSE C, FONG KY: In vivo pro- and anti-inflammatory cytokines in normal and patients with rheumatoid arthritis. Ann. Acad. Med. Singapore (2007) 36:96-99.
14. CHEN DY, LAN JL, LIN FJ, HSIEH TY: Association of intercellular adhesion molecule-1 with clinical manifestations and interleukin-18 in patients with active, untreated adult-onset Still's disease. Arthritis Rheum. (2005) 53:320-327.
15. CHEN DY, LAN JL, LIN FJ, HSIEH TY: Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease. J. Rheumatol. (2004) 31:2189-2198.
16. LOTITO AP, CAMPA A, SILVA CA, KISS MH, MELLO SB: Interleukin 18 as a marker of disease activity and severity in patients with juvenile idiopathic arthritis. J. Rheumatol. (2007) 34:823-830.
17. MIRANDA LA, FISCHER RG, SZTAJNBOK FR, JOHANSSON A, FIGUEREDO CM, GUSTAFSSON A: Increased interleukin-18 in patients with juvenile idiopathic arthritis and early attachment loss. J. Periodontol. (2005) 76:75-82.
18. HULTHE J, MCPHEAT W, SAMNEGARD A, TORNVALL P, HAMSTEN A, ERIKSSON P: Plasma interleukin (IL)-18 concentrations is elevated in patients with previous myocardial infarction and related to severity of coronary atherosclerosis independently of C-reactive protein and IL-6. Atherosclerosis (2006) 188:450-454.
19. PETERSEN AM, PENKOWA M, IVERSEN M et al.: Elevated levels of IL-18 in plasma and skeletal muscle in chronic obstructive pulmonary disease. Lung (2007) 185:161-171.
20. HOSHINO T, KATO S, OKA N et al.: Pulmonary inflammation and emphysema: role of the cytokines IL-18 and IL-13. Am. J. Respir. Crit. Care Med. (2007) 176:49-62.
21. LEE KS, KIM SR, PARK SJ et al.: Antioxidant down-regulates interleukin-18 expression in asthma. Mol. Pharmacol. (2006) 70:1184-1193.
22. SHIN HD, KIM LH, PARK BL et al.: Association of interleukin 18 (IL18) polymorphisms with specific IgE levels to mite allergens among asthmatic patients. Allergy (2005) 60:900-906.
23. LUDWICZEK O, KASER A, NOVICK D, DINARELLO CA, RUBINSTEIN M, TILG H: Elevated systemic levels of free interleukin-18 (IL-18) in patients with Crohn's disease. Eur. Cytokine Netw. (2005) 16:27-33.
24. TAMURA K, FUKUDA Y, SASHIO H et al.: IL18 polymorphism is associated with an increased risk of Crohn's disease. J. Gastroenterol. (2002) 37(Suppl.):111-116.
25. WIERCINSKA-DRAPALO A, FLISIAK R, JAROSZEWICZ J, PROKOPOWICZ D: Plasma interleukin-18 reflects severity of ulcerative colitis. World J. Gastroenterol. (2005) 11:605-608.
26. TAKEUCHI D, YOSHIDOME H, KATO A et al.: Interleukin 18 causes hepatic ischemia/reperfusion injury by suppressing anti-inflammatory cytokine expression in mice. Hepatology (2004) 39:699-710.
27. FALASCA K, UCCIFERRI C, DALESSANDRO M et al.: Cytokine patterns correlate with liver damage in patients with chronic hepatitis B and C. Ann. Clin. Lab. Sci. (2006) 36:144-150.
28. VECCHIET J, FALASCA K, CACCIATORE P et al.: Association between plasma interleukin-18 levels and liver injury in chronic hepatitis C virus infection and non-alcoholic fatty liver disease. Ann. Clin. Lab. Sci. (2005) 35:415-422.
29. HOMSI E, JANINO P, DE FARIA JB: Role of caspases on cell death, inflammation, and cell cycle in glycerol-induced acute renal failure. Kidney Int. (2006) 70:1666.
30. FAUBEL S, LEWIS EC, REZNIKOV L: Cisplatin-induced acute renal failure is associated with an increase in the cytokines interleukin (IL)-1β, IL-18, IL-6, and neutrophil infiltration in the kidney. J. Pharmacol. Exp. Ther. (2007) 322:8-15.
31. TSCHOEKE SK, OBERHOLZER A, MOLDAWER LL: Interleukin-18: a novel prognostic cytokine in bacteria-induced sepsis. Crit. Care Med. (2006) 34:1225-1233.
32. TOOULI J, BROOKE-SMITH M, BASSI C et al.: Working party of the program commitee of the Bangkok world congress of gastroenterology 2002. Guidelines for the management of acute pancreatitis. J. Gastroenterol. Heoatol. (2002) 17(Suppl.):S15-S39.
33. DINARELLO CA: Interleukin-18 and the pathogenesis of inflammatory diseases. Semin. Nephrol. (2007) 27:98-114.
34. TORIGOE K, USHIO S, OKURA T et al.: Purification and characterization of the human interleukin-18 receptor. J. Biol. Chem. (1997) 272:25737-25742.
35. THOMASSEN E, BIRD TA, RENSHAW BR, KENNEDY MK, SIMS JE: Binding of interleukin-18 to the interleukin-1 receptor homologous receptor IL-1 Rrp1 leads to activation of signaling pathways similar to those used by interleukin-1. J. Interferon Cytokine Res. (1998) 18:1077-1088.
36. BORN TL, THOMASSEN E, BIRD TA, SIMS JE: Cloning of a novel receptor subunit, AcPL, required for interleukin-18 signaling. J. Biol. Chem. (1998) 273:29445-29450.
37. ADACHI O, KAWAI T, TAKEDA K et al.: Targeted disruption of the MyD88 gene resul ts in loss of IL-1- and IL-18-mediated function. Immunity (1998) 9:143-150.
38. TAKEDA K, KAISHO T, AKIRA S: Toll-like receptors. Annu. Rev. Immunol. (2003) 21:335-376.
39. SUZUKI N, SUZUKI S, DUNCAN GS et al.: Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4. Nature (2002) 416:750-756.
40. WANG C, DENG L, HONG M, AKKARAJU GR, INOUE J, CHEN ZJ: TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature (2001) 412:346-351.
41. DENG L, WANG C, SPENCER E et al.: Activation of the IκB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell (2000) 103:351-361.
42. WERESZCZYNSKA-SIEMIATKOWSKA U, MROCZKO B, SIEMIATKOWSKI A: Serum profiles of interleukin-18 in different severity forms of human acute pancreatitis. Scand. J. Gastroenterol. (2002) 37:1097-1102.
43. UEDA T, TAKEYAMA Y, YASUDA T et al.: Significant elevation of serum interleukin-18 levels in patients with acute pancreatitis. J. Gastroenterol. (2006) 41:158-165.
44. RAU B, BAUMGART K, PASZKOWSKI AS, MAYER IM, BEGER HG: Clinical relevance of caspase-1 activated cytokines in acute pancreatitis: high correlation of serum interleukin-18 with pancreatic necrosis and systemic complications. Crit. Care Med. (2001) 29:1556-1562.
45. PEREIASLOV AA, CHUKLIN SM, POSIVNYCH MM: Pathogenesis and treatment of haemocoagulation disorders in acute necrotic pancreatitis. Klinicheskaia Khirurhiia (2006) 10:26-29.
46. WORKING PARTY OF THE BRITISH SOCIETY OF GASTROENTEROLOGY; ASSOCIATION OF SURGEONS OF GREAT BRITAIN AND IRELAND; PANCREATIC SOCIETY OF GREAT BRITAIN AND IRELAND; ASSOCIATION OF UPPER Gl SURGEONS OF GREAT BRITAIN AND IRELAND: UK guidelines for the management of acute pancreatitis. Gut (2005) 54(Suppl. 3):1-9.
47. TALAMINI G, UOMO G, PEZZILLI R et al.: Serum creatinine and chest radiographs in the early assessment of acute pancreatitis. Am. J. Surg. (1999) 177:7-14.
48. PEZZILLI R, FANTINI L, MORSELLI-LABATE AM: New approaches for the treatment of acute pancreatitis. J. Pancreas (2006) 7:79-91.
49. PEZZILLI R, BILLI P, MINIERO R et al.: Serum interieukin-6, interleukin-8, and β2-microglobulin in early assessment of severity of acute pancreatitis. Comparison with serum C-reactive protein. Dig. Dis. Sci. (1995) 40:2341-2348.
50. TRINCHIERI G: Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol. (1995) 13:251-276.
51. ROBINSON D, SHIBUYA K, MUI A et al.: IGIF does not drive Th1 development but synergizes with IL-12 for interferon-γ production and activates IRAK and NF-κB. Immunity (1997) 7:571-581.
52. PEZZILLI R, MINIERO R, CAPPELLETTI O, BARAKAT B: Behavior of serum interleukin 12 in human acute pancreatitis. Pancreas (1999) 18:247-251.
53. FIRESTEIN GS, ALVARO-GARCIA JM, MAKI R: Quantitative analysis of cytokinc gene expression in rheumatoid arthritis. J. Immunol. (1990) 144:3347-3353.
54. FELDMANN M, BRENNAN FM, MAINI RN: Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. (1996) 14:397-440.
55. DINARELLO CA: Interleukin-18, a proinflammatory cytokine. Eur. Cytokine Netw. (2000) 11:483-486.
56. RAU BM, KRUGER CM, SCHILLING MK: Anti-cytokine strategies in acute pancreatitis: pathophysiological insights and clinical implications. Rocz Akad. Med. Bialymst. (2005) 50:106-115.
57. + human blood mononuclear cells. J. Clin. Invest. (1998) 101:711-721.
58. ENDO S, INOUE Y, FUJINO Y, WAKABAYASHI G, INADA K, SATO S: Interleukin 18 levels reflect the severity of acute pancreatitis. Res. Commun. Mol. Pathol. Pharmacol. (2001) 110:285-291.
59. RAU B, POCH B, GANSAUGE F et al.: Pathophysiologic role of oxygen free radicals in acute pancreatitis: initiating event or mediator of tissue damage? Ann. Surg. (2000) 231:352-360.
60. WERESZCZYNSKA-SIEMIATKOWSKA, DABROWSKI A, JEDYNAK M, GABRYELEWICZ A: Oxidative stress as an early prognostic factor in acute pancreatitis (AP): its correlation with serum phospholipase A2 (PLA2) and plasma polymorphonuclear elastase (PMN-E) in different-severity forms of human AP. Pancreas (1998) 17:163-168.
61. WERESZCZYNSKA-SIEMIATKOWSKA U, DABROWSKI A, SIEMIATKOWSKI A, MROCZKO B, LASZEWICZ W, GABRYELEWICZ A: Serum profiles of E-selectin, interleukin-10, and interleukin-6 and oxidative stress parameters in patients with acute pancreatitis and nonpancreatic acute abdominal pain. Pancreas (2003) 26:144-152.
62. BRAGANZA JM, SCOTT P, BILTON D et al.: Evidence for early oxidative stress in acute pancreatitis. Clues for correction. Int. J. Pancreatol. (1995) 17:69-81.
63. RAYMAN MP: The importance of selenium to human health. Lancet (2000) 356:233-241.
64. SCHULZ HU, PAGE L, HALANGK W, LIPPERT H: Plasma lipid peroxide and selenium levels in acute pancreatitis. 1st Combined Meeting of the European Pancreatic Club and the International Association of Pancreatology. Mannheim, Germany (12-15 June 1996). Digestion (1996) 57:215-283 (Abstract).
65. SZUSTER-CIESIELSKA A, DANILUK J, KANDEFER-SZERSZEN M: Oxidative stress in blood of patients with alcohol-related pancreatitis. Pancreas (2001) 22:261-266.
66. VIEDMA CONTRERAS JA: Leukocyte activation markers in clinical practice. Clin. Chem. Lab. Med. (1999) 37:607-622.
67. FROSSARD JL, HADENGUE A, PASTOR CM: New serum markers for the detection of severe acute pancreatitis in humans. Am. J. Respir. Crit. Care Med. (2001) 164:162-170.
68. WERESZCZYNSKA-SIEMIATKOWSKA U, MROCZKO B, SIEMIATKOWSKI A, SZMITKOWSKI M, BORAWSKA M, KOSEL J: The importance of interleukin 18, glutathione peroxidase, and selenium concentration changes in acute pancreatitis. Dig. Dis. Sci. (2004) 49:642-650.
69. SHIBATA M, HIROTA M, NOZAWA F, OKABE A, KURIMOTO M, OGAWA M: Increased concentrations of plasma IL-18 in patients with hepatic dysfunction after hepatectomy. Cytokine (2000) 12:1526-1530.
70. SHIBATA M, HIROTA M, INOUE K, OGAWA M: Contribution of IL-18 and its related cytokines on the development of hepatic dysfunction in non-biliary acute pancreatitis. Int. Congress Series (2003) 1255:159-165.
71. NISHIOKA T, KUROISHI T, SUGAWARA Y et al.: Induction of serum IL-18 with Propionibacterium acnes and lipopolysaccharide in phagocytic macrophage-inactivated mice. J. Leukoc. Biol. (2007) (In Press).
72. TSUTSUI H, MATSUI K, KAWADA N et al.: IL-18 accounts for both TNF-α- and Fas ligand-mediated hepatotoxic pathways in endotoxin-induced liver injury in mice. J. Immunol. (1997) 159:3961-3967.
73. TSUTSUI H, MATSUI K, OKAMURA H, NAKANISHI K: Pathophysiological roles of interleukin-18 in inflammatory liver diseases. Immunol. Rev. (2000) 174:192-209.
74. FINOTTO S, SIEBLER J, HAUSDING M et al.: Severe hepatic injury in interleukin 18 (IL-18) transgenic mice: a key role for IL-18 in regulating hepatocyte apoptosis in vivo. Gut (2004) 53:1058.
75. TAKEUCHI D, YOSHIDOME H, KATO A et al.: Interleukin 18 causes hepatic ischemia/reperfusion injury by suppressing anti-inflammatory cytokine expression in mice. Hepatology (2004) 39:699-710.
76. FAUBEL S, EDELSTEIN CL: Caspases as drug targets in ischemic organ injury. Curr. Drug Targets Immune Endocr. Metabol. Disord. (2005) 5:269-287.
77. TAKEYAMA Y, HORI Y, TAKASE K, UEDA T, YAMAMOTO M, KURODA Y: Apoptotic cell death of hepatocytes in rat experimental severe acute pancreatitis. Surgery (2000) 127:55-64.
78. HORI Y, TAKEYAMA Y, UEDA T, SHINKAI M, TAKASE K, KURODA Y: Macrophage-derived transforming growth factor-β1 induces hepatocellular injury via apoptosis in rat severe acute pancreatitis. Surgery (2000) 127:641-649.
79. KRAMS SM, EGAWA H, QUINN MB, VILLANUEVA JC, GARCIA-KENNEDY R, MARTINEZ OM: Apoptosis as a mechanism of cell death in liver allograft rejection. Transplantation (1995) 59:621-625.
80. UEDA T, TAKEYAMA Y, TAKASE K, HORI Y, KURODA Y, HO HS: Hematin is one of the cytotoyic factors in pancreatitis-associated ascitic fluid that causes hepatocellular injury. Surgery (2002) 131:66-74.
81. YUMOTO E, HIGASHI T, NOUSO K et al.: Serum γ-interferon-inducing factor (IL-18) and IL-10 levels in patients with acute hepatitis and fulminant hepatic failure. J. Gastroenterol. Hepatol. (2002) 17:285-294.
82. BLINDENBACHER A, WANG X, LANGER I et al.: Interleukin 6 is important for survival after partial hepatectomy in mice. Hepatology (2003) 38:674-682.
83. MARINO E, CARDIER JE: Differential effect of IL-18 on endothelial cell apoptosis mediated by TNF-α and Fas (CD95). Cytokine (2003) 22:142-148.
84. SIVALINGAM SP, THUMBOO J, VASOO S, FONG KY: HLA-DRB1 *04 gene polymorphisms and expressions profiles of interleukin-18 and interleukin-18 binding protein following in vitro stimulation in human peripheral blood mononuclear cells of healthy individuals and patients with rheumatoid arthritis. Life Sci. (2007) 80:1887-1896.
85. SMEETS RL, VAN DE LOO FA, ARNTZ OJ et al.: Adenoviral delivery of IL-18 binding protein C ameliorates collagen-induced arthritis in mice. Gene Ther. (2003) 10:1004-1011.
86. BANDA NK, VONDRACEK A, KRAUS D et al.: Mechanisms of inhibition of collagen-induced arthritis by murine IL-18 binding protein. J. Immunol. (2003) 170:2100-2105.
87. PLATER-ZYBERK C, JOOSTEN LA, HELSEN MM et al.: Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. J. Clin. Invest. (2001) 108:1825-1832.
88. WILDBAUM G, YOUSSEF S, GRABIE N, KARIN N: Neutralizing antibodies to IFN-γ-inducing factor prevent experimental autoimmune encephalomyelitis. J. Immunol. (1998) 161:6368-6374.
89. IM SH, BARCHAN D, MAITI PK, RAVEH L, SOUROUJON MC, FUCHS S: Suppression of experimental myasthenia gravis, a B cell-mediated autoimmune disease, by blockade of IL-18. FASEB J. (2001) 15:2140-2148.
90. SOUROUJON MC, MAITI PK, FEFERMAN T, IM SH, RAVEH L, FUCHS S: Suppression of myasthenia gravis by antigen-specific mucosal tolerance and modulation of cytokines and costimulatory factors. Ann. NY Acad. Sci. (2003) 998:533-536.
91. PISKIN G, TURSEN U, SYLVA-STEENLAND RM, BOS JD, TEUNISSEN MB: Clinical improvement in chronic plaque-type psoriasis lesions after narrow-band UVB therapy is accompanied by a decrease in the expression of IFN-γ inducers - IL-12, IL-18 and IL-23. Exp. Dermatol. (2004) 13:764-772.
92. NUMEROF RP, DINARELLO CA, ASADULLAH K: Cytokines as potential therapeutic targets for inflammatory skin diseases. Eur. Cytokine Netw. (2005) 16:101-103.
93. NUMEROF RP, ASADULLAH K: Cytokine and anti-cytokine therapies for psoriasis and atopic dermatitis. Biodrugs (2006) 20:93-103.
94. BOSS P, NEUMANN D, DEL GIUDICE E et al.: IL-18 cDNA vaccination protects mice from spontaneous lupus-like autoimmune disease. Proc. Natl. Acad. Sci. USA (2003) 100:14181-14186.
95. NOLD M, HAUSER IA, HOFLER S et al.: IL-18BPa:Fc cooperates with immunosuppressive drugs in human whole blood. Biochem. Pharmacol. (2003) 66:505-510.
96. NICOLETTI F, DI MARCO R, PAPACCIO G et al.: Essential pathogenic role of endogenous IL-18 in murine diabetes induced by multiple low doses of streptozotocin. Prevention of hyperglycemia and insulitis by a recombinant IL-18-binding protein: Fc construct. Eur. J. Immunol. (2003) 33:2278-2286.
97. ZACCONE, HILLIPS J, CONGET I, COOKE A, NICOLETTI F: IL-18 binding protein fusion construct delays the development of diabetes in adoptive transfer and cyclophosphamide-induced diabetes in NOD mouse. Clin. Immunol. (2005) 115:74-79.
98. FAGGIONI R, JONES-CARSON J, REED DA et al.: Leptin-deficient (ob/ ob) mice are protected from T cell-mediated hepatotoxicity: role of TNF-α and IL-18. Proc. Natl. Acad. Sci. USA (2000) 97:2367-2372.
99. FANTUZZI G, BANDA NK, GUTHRIDGE C et al.: Generation and characterization of mice transgenic for human IL-18-binding protein isoform A. J. Leuk. Biol. (2003) 74:889-896.
100. NETEA MG, FANTUZZI G, KULLBERG BJ et al.: Neutralization of IL-18 reduces neutrophil tissue accumulation and protects mice against lethal Escherichia coli and Salmonella typhimurium endotoxemia. J. Immunol. (2000) 164:2644-2649.
101. MELNIKOV VY, ECDER T, EANTUZZI G et al.: Impaired IL-18 processing protects caspase-1-deficient mice from ischemic acute renal failure. J. Clin. Invest. (2001) 107:1145-1152.
102. RAEBURN CD, DINARELLO CA, ZIMMERMAN MA et al.: Neutralization of IL-18 attenuates lipopolysaccharide-induced myocardial dysfunction. Am. J. Physiol. Heart Circ. Physiol. (2002) 283:650-657.
103. RAU B, ZHUANG Y, SCHOELER C, HANS J, TILTON B, SCHILLING M: Caspase-1 activated cytokines in experimental acute pancreatitis: synergistic effects of IL-1β and IL-18 on the development of disease severity. Pancreas (2003) 27:403-404.
104. PERREGAUX DG, MCNIFF P, LALIBERTE R et al.: Identification and characterization of a novel class of interleukin-1 post-translational processing inhibitors. J. Pharmacol. Exp. Ther. (2001) 299:187-197.
105. 7 receptor antagonists. Bioorg. Med. Chem. Lett. (2003) 13:4047-4050.
106. 7 receptor antagonists. Bioorg. Med. Chem. Lett. (2003) 13:4043-4046.
107. HONORE P, DONNELLY-ROBERTS D, NAMOVIC MT et al.: A-740003 [N-(1-{[(cyanoimino)(5-quinolinylamino) methyl]amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a novel and selective P2X7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat. J. Pharmacol. Exp. Ther. (2006) 319:1376-1385.
108. STOKES L, JIANG LH, ALCARAZ L et al.: Characterization of a selective and potent antagonist of human P2X(7) receptors, AZ11645373. Br. J. Pharmacol. (2006) 149:880-887.
109. 7 receptor, an important inflammatory target. J. Org. Chem. (2007) 72:2309-2317.
110. MEHTA VB, HART J, WEWERS MD: ATP-stimulated release of interleukin (IL)-1β and IL-18 requires priming by lipopolysaccharide and is independent of caspase-1 cleavage. J. Biol. Chem. (2001) 276:3820-3826.
111. ZHANG XH, ZHU RM, XU WA, WAN HJ, LU H: Therapeutic effects of caspase-1 inhibitors on acute lung injury in experimental severe acute pancreatitis. World J. Gastroenterol. (2007) 13:623-627.
112. NORMAN J, YANG J, FINK G et al.: Severity and mortality of experimental pancreatitis are dependent on interleukin-1 converting enzyme (ICE). J. Interferon Cytokine Res. (1997) 17:113-118.
113. RAUB, PASZKOWSKI A, LILLICH S, BAUMGART K, MOLLER P, BEGER HG: Differential effects of caspase-1/interleukin-1β-converting enzyme on acinar cell necrosis and apoptosis in severe acute experimental pancreatitis. Lab. Invest. (2001) 81:1001-1013.
114. PASZKOWSKI AS, RAU B, MAYER JM, MOLLER P, BEGER HG: Therapeutic application of caspase 1/interleukin-1β-converting enzyme inhibitor decreases the death rate in severe acute experimental pancreatitis. Ann. Surg. (2002) 235:68-76.
115. NORMAN J, FRANZ M, MESSINA J: Interleukin-1 receptor antagonism decreases severity of experimental acute pancreatitis. Surgery (1995) 117:648-655.
116. NORMAN JG, FRANZ MG, FINK GS: Decreased mortality of severe acute pancreatitis after proximal cytokine blockade. Ann. Surg. (1995) 221:625-631.
117. MAYER J, RAU B, GANSAUGE F, BEGER HG: Inflammatory mediators in human acute pancreatitis: clinical and pathophysiologicall implications. Gut (2000) 47:546-552.
118. OBERHOLZER A, FEILNER A, HENTZE H et al.: Sepsis after severe injury interrupts caspase-dependent processing of interleukin-18. J. Trauma (2000) 49:11-16.
119. SUGAWARA S, UEHARA A, NOCHI T et al.: Neutrophil proteinase 3-mediated induction of bioactive IL-18 secretion by human oral epithelial cells. J. Immunol. (2001) 167:6568-6575.
120. PIRHONEN J, SARENEVA T, JULKUNEN I, MATIKAINEN S: Virus infection induces proteolytic processing of IL-18 in human macrophages via caspase-1 and caspase-3 activation. Eur. J. Immunol. (2001) 31:726-733.
121. KORKMAZ B, HAJJAR E, KALUPOV T et al.: Influence of charge distribution at the active site surface on the substrate specificity of human neutrophil protease 3 and elastase. A kinetic and molecular modeling analysis. J. Biol. Chem. (2007) 282:1989-1997.
122. IKAWA K, NISHIOKA T, YU Z et al.: Involvement of neutrophil recruitment and protease-activated receptor 2 activation in the induction of IL-18 in mice. J. Leuk. Biol. (2005) 78:1118-1126.
123. DINARELLO CA, FANTUZZI G: Interleukin-18 and host defense against infection. J. Infect. Dis. (2003) 187(Suppl. 2):S370-S384.
124. TAKEDA K, TSUTSUI H, YOSHIMOTO T et al.: Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity (1998) 8:383-390.
125. LOGAN TF, ROBERTSON MJ: Interleukins 18 and 21: biology, mechanisms of action, toxicity, and clinical activity. Curr. Oncol. Rep. (2006) 8:114-119.
126. HWANG KS, CHO WK, YOO J et al.: Adenovirus-mediated interleukin-18 mutant in vivo gene transfer inhibits tumor growth through the induction of T cell immunity and activation of natural killer cell cytotoxicity. Cancer Gene Ther. (2004) 11:397-407.
127. GOLAB J, STOKLOSA T: Technology evaluation: SB-485232, GlaxoSmithKline. Curr. Opin. Mol. Ther. (2005) 7:85-93.
128. DUMONT FJ: The interleukin-1 families of cytokines and receptors: therapeutic potential for immunomodulation and the treatment of inflammatory disorders. Expert Opin. Ther. Patents (2006) 16:879-912.